Thermo Fisher to Acquire Solventum’s Filtration Unit for $4.1B in Bioprocessing Expansion

Thermo Fisher Scientific has announced a $4.1 billion cash acquisition of Solventum’s purification and filtration business, a unit specializing in biopharmaceutical, medical, and industrial filtration technologies. The acquisition will integrate the business into Thermo Fisher’s life sciences solutions segment, boosting its capabilities in bioprocessing, particularly in biologics manufacturing.

The deal, expected to close by the end of the year, is projected to drive mid- to high-single-digit organic growth while improving operating margins. Solventum, a 3M spinoff, plans to use the estimated $3.4 billion in net proceeds to pay down debt and refine its strategic focus. Wall Street reacted positively to the news, with Solventum’s stock surging 10% following the announcement.